Literature DB >> 1817043

Biochemical abnormalities in cerebrotendinous xanthomatosis.

G Salen1, S Shefer, V Berginer.   

Abstract

Cerebrotendinous xanthomatosis (CTX) is a rare recessive inherited lipid storage disease that was first described by Van Bogaert. Although the principal clinical presentation affects the nervous system with dementia, spinal cord paresis, cerebellar ataxia and peripheral neuropathy, the liver is is the organ where the major biochemical abnormalities are expressed. The following sections deal with the pathogenesis and treatment of the biochemical problems in CTX.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1817043     DOI: 10.1159/000112186

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  5 in total

1.  Cerebrotendinous xanthomatosis: heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings.

Authors:  M T Dotti; A Rufa; A Federico
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

2.  Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.

Authors:  Maria Del Mar Amador; Marion Masingue; Rabab Debs; Foudil Lamari; Vincent Perlbarg; Emmanuel Roze; Bertrand Degos; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2018-03-20       Impact factor: 4.982

Review 3.  Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).

Authors:  Gerald Salen; Robert D Steiner
Journal:  J Inherit Metab Dis       Date:  2017-10-04       Impact factor: 4.982

4.  Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin.

Authors:  E Leitersdorf; A Reshef; V Meiner; R Levitzki; S P Schwartz; E J Dann; N Berkman; J J Cali; L Klapholz; V M Berginer
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

Review 5.  Psychiatric manifestations in cerebrotendinous xanthomatosis.

Authors:  M J Fraidakis
Journal:  Transl Psychiatry       Date:  2013-09-03       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.